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and diffuse long lesion group (more than 30 mm, n=127).
Results: Baseline clinical characteristics & procedure details were similar between the
two groups, except pts with diffuse long lesion were more smokers (59.1% vs. 46.3
%, p: 0.044). In long lesion group; use of retrograde approach, numbers of wires,
microcatheter, amount of dye and total fluoroscopy time, were higher. Except for
perforation, procedure related complications were similar between the two groups. At
one year, diffuse long lesion group showed worse clinical outcomes including higher
incidence of target lesions revascularization (TLR), target vessel revascularization
(TVR) and TLR-major adverse cardiac events (MACE, Table).
Conclusion: Diffuse long CTO lesions needed more complex procedure techniques
and devices. Further, those were associated with worse clinical outcomes at one year
follow up as compared with shorter CTO lesions.
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Background: Stent fracture is related to restenosis after drug-eluting stent (DES)
implantation. As percutaneous coronary intervention (PCI) cases for complex lesions
increase, those for stent fracture-related restenosis could also increase. However, the
optimal PCI strategy for such restenosis remains unclear. We evaluated the results of
PCI with plain old balloon angioplasty (POBA), DES, and drug-eluting balloon (DEB,
SeQuent Please) for restenosis with stent fracture after sirolimus-eluting stent (SES)
implantation.
Methods: From November 2002 to October 2010, 5334 patients with 6299 lesions
underwent SES implantation successfully. Of these lesions, 5298 were angiographically
followed after 6 to 8 months (midterm f/u) and 3981 were followed at 12 months after
midterm f/u (late f/u). Stent fracture occurred at 294 lesions (stent fracture rate, 5.5%)
and stent fracture with restenosis occurred at 123 lesions. Of these 123 lesions, target
lesion revascularization (TLR) by PCI with POBA, DES, or DEB was performed on
80 lesions.
Results: Data are shown in the table. At midterm f/u, the rates of restenosis and TLR
after restenting with DES were significantly lower than those after POBA. At late f/u,
there was no significant difference between POBA and DES. Late f/u was not
performed on the DEB cases.
Conclusion: Restenting with DES could be an acceptable treatment for restenosis with
stent fracture after SES implantation.
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Background: The number of PCI has been increasing during the last years in Europe.
Little is known about the characteristics of interventional treatment of in-stent-re-
stenosis (ISR) in clinical practice in Europe.
Methods: Between 2005 and 2008, 47,407 consecutive patients undergoing PCI were
enrolled into the PCI-Registry of the Euro Heart Survey Programme to document
patient characteristics, PCI details and hospital complications in different PCI
indications. We examined the differences between treatment of ISR versus de novo-
lesions in patients undergoing PCI for ACCS in clinical practice.
Results: A total of 14,011 patients underwent PCI for ACS, in 789 (5.6%) the treated
culprit lesion was an ISR. Patients with ISR more often were male; more often had
diabetes, prior MI and CABG than patients undergoing PCI in de-novo lesions. No
differences were found in the use of anti-thrombotic drugs despite a more frequent use
of GP IIb/IIIa receptor blockers even in patients with de-novo lesions rather than in
ISR. In ISR, 70.1% of patients did receive a stent, of which 64.6% were DES. The rate
of stenting in de-novo lesions was 94.8%, with a relative proportion of 38.0% of DES.
No differences were observed in hospital outcome.
Conclusion: The culprit lesion in consecutive patients undergoing PCI for ACS in
clinical practice in Europe was ISR in 5.6%. Patients with ACS treated for ISR less
often received new stents, of which only two third were DES. No differences were
found in hospital clinical outcome between patients with ISR or de-novo- stenosis in
ACS in clinical practice in Europe.
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Background: As Drug-eluting stents (DES) significantly reduce the risk of in-stent
restenosis (ISR), it has become common practice to perform PCI with DES for
unprotected distal left main (UDLM) stenosis. However, there is little available data
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